Literature DB >> 16631262

Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin.

James F List1, Huile He, Joel F Habener.   

Abstract

Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone expressed by alternative post-translational processing of proglucagon in the intestines, endocrine pancreas, and brain. The multiple antidiabetogenic actions of GLP-1 include stimulation of the proliferation and differentiation of the insulin-producing beta cells in the pancreas. The GLP-1 receptor is widely distributed and has been identified in the endocrine pancreas, intestinal tract, brain, lung, kidney, and heart. Here we report the expression of the GLP-1 receptor and proglucagon in the skin of newborn mice located predominantly in the hair follicles, as well as in cultures of skin-derived cells that also express nestin, a marker of cultured cells that have dedifferentiated by epithelial to mesenchymal transition. In cultured skin cells, GLP-1 activates the MAPK/ERK signal transduction pathway, associated with cellular proliferation, differentiation, and cytoprotection. No evidence was found for the activation of cAMP or Ca2+ signaling pathways. Further, redifferentiation of cultured skin-derived cells by incubation in differentiation medium containing GLP-1 induced expression of the proinsulin-derived peptide, C-peptide. These findings suggest a possible paracrine/autocrine role for GLP-1 and its receptor in skin development and possibly also in folliculogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631262     DOI: 10.1016/j.regpep.2006.02.007

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Authors:  C G Jolivalt; M Fineman; C F Deacon; R D Carr; N A Calcutt
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

2.  Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.

Authors:  Wei Jing Liu; Heung Yong Jin; Kyung Ae Lee; Shu Hua Xie; Hong Sun Baek; Tae Sun Park
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

3.  Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.

Authors:  D J Drucker; C F Rosen
Journal:  Diabetologia       Date:  2011-09-03       Impact factor: 10.122

4.  PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.

Authors:  Taichi Nakamura; Tetsuhide Ito; Masahiko Uchida; Masayuki Hijioka; Hisato Igarashi; Takamasa Oono; Masaki Kato; Kazuhiko Nakamura; Koichi Suzuki; Robert T Jensen; Ryoichi Takayanagi
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

5.  Protection of exendin-4 analogue in early experimental diabetic retinopathy.

Authors:  Yu Zhang; Qingping Wang; Jingfa Zhang; Xia Lei; Guo-Tong Xu; Wen Ye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-16       Impact factor: 3.117

6.  An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.

Authors:  Georgios Kyriakos; Evangelos Diamantis; Eleni Memi; Ioannis Elefsiniotis
Journal:  Cureus       Date:  2022-01-23

Review 7.  Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.

Authors:  Silvano Paternoster; Marco Falasca
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.